Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Dacomitinib in Advanced NSCLC
NCT01858389Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2013
- Primary completion
- Sep 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label trial of dacomitinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Pfizer. Primary endpoints: Best Overall Response up to 61 weeks and Objective Response Rate up to 61 weeks. Started Jul 2013; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01858389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01858389.